Clematichinenoside C is primarily studied for its anti-inflammatory and neuroprotective properties. It has shown potential in alleviating symptoms of neurodegenerative disorders such as Alzheimer's disease by reducing oxidative stress and inhibiting the production of pro-inflammatory cytokines in brain tissues. Research indicates it may help protect neurons from damage caused by beta-amyloid peptides, which are implicated in Alzheimer's pathology.

It also exhibits cardioprotective effects, particularly in models of myocardial ischemia-reperfusion injury, where it helps reduce infarct size and improve heart function by modulating apoptotic pathways and suppressing inflammation.

Additionally, Clematichinenoside C has demonstrated anti-arthritic activity in preclinical models of rheumatoid arthritis, where it suppresses joint inflammation and cartilage degradation by downregulating key inflammatory mediators like TNF-α, IL-6, and NF-κB signaling.

Due to these biological activities, it is considered a candidate for developing natural product-based therapies for chronic inflammatory and neurodegenerative diseases, though clinical data remain limited and further studies are needed.